Xenon Pharmaceuticals logo

Xenon Pharmaceuticals Inc. (NASDAQ:XENEGet Rating) was the recipient of unusually large options trading activity on Wednesday. Traders acquired 4,063 put options on the stock. This is an increase of 2,362% compared to the average volume of 165 put options.

Shares of XENE opened at $28.74 on Friday. Xenon Pharmaceuticals has a 1-year low of $14.65 and a 1-year high of $36.42. The stock has a market cap of $1.53 billion, a PE ratio of -16.06 and a beta of 1.76. The firm has a 50-day simple moving average of $29.63 and a two-hundred day simple moving average of $29.70.

Xenon Pharmaceuticals (NASDAQ:XENEGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. Xenon Pharmaceuticals had a negative net margin of 360.80% and a negative return on equity of 20.94%. The business had revenue of $8.77 million during the quarter, compared to analysts’ expectations of $9.22 million. During the same period last year, the business earned ($0.42) earnings per share. Equities analysts forecast that Xenon Pharmaceuticals will post -2.04 earnings per share for the current year.

(Ad)

What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. increased its position in shares of Xenon Pharmaceuticals by 177.7% during the fourth quarter. Point72 Asset Management L.P. now owns 2,992,597 shares of the biopharmaceutical company’s stock valued at $93,489,000 after acquiring an additional 1,914,797 shares during the last quarter. Perceptive Advisors LLC grew its holdings in shares of Xenon Pharmaceuticals by 19.3% in the fourth quarter. Perceptive Advisors LLC now owns 2,411,447 shares of the biopharmaceutical company’s stock valued at $75,334,000 after purchasing an additional 389,396 shares in the last quarter. Capital World Investors grew its holdings in shares of Xenon Pharmaceuticals by 136.1% in the fourth quarter. Capital World Investors now owns 2,274,974 shares of the biopharmaceutical company’s stock valued at $71,070,000 after purchasing an additional 1,311,474 shares in the last quarter. Polar Capital Holdings Plc grew its holdings in shares of Xenon Pharmaceuticals by 29.7% in the first quarter. Polar Capital Holdings Plc now owns 2,190,059 shares of the biopharmaceutical company’s stock valued at $66,950,000 after purchasing an additional 502,015 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in shares of Xenon Pharmaceuticals by 3,996.8% in the fourth quarter. Marshall Wace LLP now owns 1,220,957 shares of the biopharmaceutical company’s stock valued at $38,143,000 after purchasing an additional 1,191,154 shares in the last quarter.

Several equities analysts have recently weighed in on XENE shares. Wedbush reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Wednesday, March 2nd. StockNews.com raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 23rd. TheStreet raised shares of Xenon Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Monday, March 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Wednesday, March 2nd. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $44.00.

Xenon Pharmaceuticals Company Profile (Get Rating)

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Xenon Pharmaceuticals right now?

Before you consider Xenon Pharmaceuticals, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Xenon Pharmaceuticals wasn’t on the list.

While Xenon Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 

Source link


The above content is from google feed with the source link mentioned. If you wish to remove the content from here then contact us and it will be removed within 24 hrs.